Silence Therapeutics PLC (SLN) — Capital Reinvestment Ratio
Latest as of June 2021:
0.02x
Silence Therapeutics PLC (SLN) has a Capital Reinvestment Ratio of 0.02x as of June 2021, meaning it reinvests 0% of its operating cash flow ($26.03 Million) in capital expenditures ($439.00K). See cash generation quality of Silence Therapeutics PLC to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
$26.03 Million
USD
Capital Expenditures
$439.00K
USD
Data as of
Jun 2021
Most recent filing
Silence Therapeutics PLC Capital Reinvestment Ratio (2019–2021)
This chart tracks Silence Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Silence Therapeutics PLC (2019–2021)
Year-by-year Capital Reinvestment Ratio for Silence Therapeutics PLC from 2019 to 2021. For live market cap and broader valuation context, see market value of Silence Therapeutics PLC.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.20x | $9.19 Million | $1.80 Million | ▲ +3661.1% |
| 2019 | 0.01x | $1.73 Million | $9.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow